References
1. McCrindle BW, McCrindle BW, Rowley AH, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135:  927-999.
2. Vincent P, Quentin H, Jean-Michel G, Denis D, Olivier V, Fabien P. Giant coronary aneurysms, from diagnosis to treatment: A literature review. Arch Cardiovasc Dis 2020; 113: 159-169.
3. Sara AS, Ozge OT, Özgür Ta, Omer G, Ismail DK. Coronary Artery Aneurysms: A Review of the Epidemiology, Pathophysiology, Diagnosis, and Treatment. Front Cardiovasc Med 2020; 4: 24.
4. Burns JC, Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol 2015; 11: 819-825.
5. Janeway CJ, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
6. Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol 2015; 141: 381-387.
7. Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin Exp Immunol 2010; 162: 131-137.
8. Su R, Li ZH, Wang YY, et al. Imbalance between Th17 and regulatory T cells in patients with systemic lupus erythematosus combined EBV/CMV viraemia. Clin Exp Rheumatol 2020; 38: 864-873.
9. Jan L, Fausto P, Hendrik SK, Alla S. Altered T cell plasticity favours Th17 cells in early arthritis. Rheumatology (Oxford) 2020;59: 2754-2763.
10. Peng D, Xu BC, Wang Y, Guo H, Jiang YF. A high frequency of circulating th22 and th17 cells in patients with new onset graves’ disease. PLoS One 2013; 8: e68446.
11. Anders D, Sidsel S, Tue KR, et al. Increased levels of circulating Th17 cells in quiescent versus active Crohn’s disease. J Crohns Colitis 2020; 7:  248-255.
12. Manoochehr R, Behzad H, Mehdi K. Downregulation of Th17 cells and the related cytokines with treatment in Kawasaki disease. Immunol Lett 2014; 162: 269-275.
13. Ma L, Zhang LW, Zhuang Y, Ding YB, Chen JP. The Imbalance between Foxp3+Tregs and Th1/Th17/Th22 Cells in Patients with Newly Diagnosed Autoimmune Hepatitis. J Immunol Re. 2018; 1: e3753081.
14. Yang XY, Wang HY, Zhao XY, Wang LJ, Lv QH, Wang QQ. Th22, but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus. J Clin Immunol 2013; 33: 767-774.
15. Zhang L, Li JM, Liu XG, et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol 2011;31: 606-614.
16. Li L, Han SX, Wang H, Liu XM. Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis. Int Immunopharmacol 2015; 29: 278-284.
17. Luo Y, Yang J, Zhang C, et al. Up-regulation of miR-27a promotes monocyte-mediated inflammatory responses in Kawasaki disease by inhibiting function of B10 cells. J Leukoc Biol 2020; 107:133-144.
18. Keiichi K, Minako H, Takeshi M, et al. Plasma Exchange Downregulates Activated Monocytes and Restores Regulatory T Cells in Kawasaki Disease. Ther Apher Dial 2019; 23: 92-98.
19. Laurent D, Audrey D, Léamarie MD, Anne F, Nagib D. Echocardiographic Parameters During and Beyond Onset of Kawasaki Disease Correlate with Onset Serum N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP). Pediatr Cardiol 2020; 41: 947-954.
20. Zheng Q, Chris D, Hu J, Hannelien V, Sofie S, Jo VD, Ghislain O. Interleukin-17 regulates chemokine and gelatinase B expression in fibroblasts to recruit both neutrophils and monocytes. Immunobiology 2009; 214: 835-842.
21. Éric T, Caroline L, Béatrice G, Damien G, Philippe S. Increased IL-22- and IL-17A-Producing Mucosal-Associated Invariant T Cells in the Peripheral Blood of Patients With Ankylosing Spondylitis. Front Immunol 2018; 9: 1610.
22. Kenneth MM. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol 2010; 11: 674-680.
23. Guo C, Tan CC, Xia XH, et al. Tumour necrosis factor-α and myoglobin associated with the recovery time of coronary artery lesions in Kawasaki disease patients. J Paediatr Child Health 2020; 56: 1382-1387.
24. Zhang RL, Lo HH, Lei C, Ip N, Chen J, Law BYK. Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease. Curr Opin Pharmacol 2020; 54:72-81.